vs
Side-by-side financial comparison of BeOne Medicines Ltd. (ONC) and SCANSOURCE, INC. (SCSC). Click either name above to swap in a different company.
BeOne Medicines Ltd. is the larger business by last-quarter revenue ($1.5B vs $766.5M, roughly 2.0× SCANSOURCE, INC.). BeOne Medicines Ltd. runs the higher net margin — 4.4% vs 2.2%, a 2.3% gap on every dollar of revenue. On growth, BeOne Medicines Ltd. posted the faster year-over-year revenue change (32.8% vs 2.5%). BeOne Medicines Ltd. produced more free cash flow last quarter ($379.8M vs $28.9M). Over the past eight quarters, BeOne Medicines Ltd.'s revenue compounded faster (41.2% CAGR vs 0.9%).
BeOne Medicines Ltd.ONCEarnings & Financial Report
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
ScanSource, Inc. is a leading global specialty technology distributor offering a broad portfolio of solutions including point-of-sale systems, barcode scanning tools, cybersecurity products, cloud services and communication solutions. It primarily serves value-added resellers, managed service providers and enterprise clients across North America, Latin America and Europe, covering retail, healthcare, industrial and public sector core segments.
ONC vs SCSC — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.5B | $766.5M |
| Net Profit | $66.5M | $16.5M |
| Gross Margin | 90.5% | 13.4% |
| Operating Margin | 12.4% | 2.3% |
| Net Margin | 4.4% | 2.2% |
| Revenue YoY | 32.8% | 2.5% |
| Net Profit YoY | 143.8% | -3.3% |
| EPS (diluted) | $0.05 | $0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.5B | $766.5M | ||
| Q3 25 | $1.4B | $739.6M | ||
| Q2 25 | $1.3B | $812.9M | ||
| Q1 25 | $1.1B | $704.8M | ||
| Q4 24 | $1.1B | $747.5M | ||
| Q3 24 | $1.0B | $775.6M | ||
| Q2 24 | $929.2M | $746.1M | ||
| Q1 24 | $751.7M | $752.6M |
| Q4 25 | $66.5M | $16.5M | ||
| Q3 25 | $124.8M | $19.9M | ||
| Q2 25 | $94.3M | $20.1M | ||
| Q1 25 | $1.3M | $17.4M | ||
| Q4 24 | $-151.9M | $17.1M | ||
| Q3 24 | $-121.3M | $17.0M | ||
| Q2 24 | $-120.4M | $16.1M | ||
| Q1 24 | $-251.2M | $12.8M |
| Q4 25 | 90.5% | 13.4% | ||
| Q3 25 | 86.1% | 14.5% | ||
| Q2 25 | 87.5% | 12.9% | ||
| Q1 25 | 85.2% | 14.2% | ||
| Q4 24 | 85.8% | 13.6% | ||
| Q3 24 | 83.0% | 13.1% | ||
| Q2 24 | 85.1% | 13.0% | ||
| Q1 24 | 83.4% | 12.6% |
| Q4 25 | 12.4% | 2.3% | ||
| Q3 25 | 11.5% | 3.5% | ||
| Q2 25 | 6.7% | 3.3% | ||
| Q1 25 | 1.0% | 3.2% | ||
| Q4 24 | -7.0% | 2.5% | ||
| Q3 24 | -12.0% | 2.3% | ||
| Q2 24 | -11.5% | 2.9% | ||
| Q1 24 | -34.8% | 2.3% |
| Q4 25 | 4.4% | 2.2% | ||
| Q3 25 | 8.8% | 2.7% | ||
| Q2 25 | 7.2% | 2.5% | ||
| Q1 25 | 0.1% | 2.5% | ||
| Q4 24 | -13.5% | 2.3% | ||
| Q3 24 | -12.1% | 2.2% | ||
| Q2 24 | -13.0% | 2.2% | ||
| Q1 24 | -33.4% | 1.7% |
| Q4 25 | $0.05 | $0.75 | ||
| Q3 25 | $0.08 | $0.89 | ||
| Q2 25 | $0.06 | $0.87 | ||
| Q1 25 | $0.00 | $0.74 | ||
| Q4 24 | $-0.10 | $0.70 | ||
| Q3 24 | $-0.09 | $0.69 | ||
| Q2 24 | $-0.09 | $0.66 | ||
| Q1 24 | $-0.19 | $0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.5B | $83.5M |
| Total DebtLower is stronger | $836.4M | — |
| Stockholders' EquityBook value | $4.4B | $910.9M |
| Total Assets | $8.2B | $1.7B |
| Debt / EquityLower = less leverage | 0.19× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.5B | $83.5M | ||
| Q3 25 | $4.0B | $124.9M | ||
| Q2 25 | $2.8B | $126.2M | ||
| Q1 25 | $2.5B | $146.3M | ||
| Q4 24 | $2.6B | $110.5M | ||
| Q3 24 | $2.7B | $145.0M | ||
| Q2 24 | $2.6B | $185.5M | ||
| Q1 24 | $2.8B | $159.1M |
| Q4 25 | $836.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $4.4B | $910.9M | ||
| Q3 25 | $4.1B | $914.0M | ||
| Q2 25 | $3.8B | $906.4M | ||
| Q1 25 | $3.5B | $901.7M | ||
| Q4 24 | $3.3B | $900.7M | ||
| Q3 24 | $3.4B | $920.9M | ||
| Q2 24 | $3.4B | $924.3M | ||
| Q1 24 | $3.4B | $944.1M |
| Q4 25 | $8.2B | $1.7B | ||
| Q3 25 | $7.6B | $1.7B | ||
| Q2 25 | $6.3B | $1.8B | ||
| Q1 25 | $5.8B | $1.7B | ||
| Q4 24 | $5.9B | $1.7B | ||
| Q3 24 | $5.8B | $1.8B | ||
| Q2 24 | $5.7B | $1.8B | ||
| Q1 24 | $5.7B | $1.8B |
| Q4 25 | 0.19× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $417.3M | $30.8M |
| Free Cash FlowOCF − Capex | $379.8M | $28.9M |
| FCF MarginFCF / Revenue | 25.4% | 3.8% |
| Capex IntensityCapex / Revenue | 2.5% | 0.3% |
| Cash ConversionOCF / Net Profit | 6.28× | 1.87× |
| TTM Free Cash FlowTrailing 4 quarters | $941.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $417.3M | $30.8M | ||
| Q3 25 | $402.6M | $23.2M | ||
| Q2 25 | $263.6M | — | ||
| Q1 25 | $44.1M | $66.1M | ||
| Q4 24 | $75.2M | $-6.2M | ||
| Q3 24 | $188.4M | $44.8M | ||
| Q2 24 | $-95.6M | — | ||
| Q1 24 | $-308.6M | $160.2M |
| Q4 25 | $379.8M | $28.9M | ||
| Q3 25 | $354.5M | $20.8M | ||
| Q2 25 | $219.8M | — | ||
| Q1 25 | $-12.3M | $64.6M | ||
| Q4 24 | $-17.3M | $-8.2M | ||
| Q3 24 | $54.7M | $42.5M | ||
| Q2 24 | $-205.5M | — | ||
| Q1 24 | $-465.1M | $157.7M |
| Q4 25 | 25.4% | 3.8% | ||
| Q3 25 | 25.1% | 2.8% | ||
| Q2 25 | 16.7% | — | ||
| Q1 25 | -1.1% | 9.2% | ||
| Q4 24 | -1.5% | -1.1% | ||
| Q3 24 | 5.5% | 5.5% | ||
| Q2 24 | -22.1% | — | ||
| Q1 24 | -61.9% | 21.0% |
| Q4 25 | 2.5% | 0.3% | ||
| Q3 25 | 3.4% | 0.3% | ||
| Q2 25 | 3.3% | 0.3% | ||
| Q1 25 | 5.0% | 0.2% | ||
| Q4 24 | 8.2% | 0.3% | ||
| Q3 24 | 13.3% | 0.3% | ||
| Q2 24 | 11.8% | 0.2% | ||
| Q1 24 | 20.8% | 0.3% |
| Q4 25 | 6.28× | 1.87× | ||
| Q3 25 | 3.22× | 1.17× | ||
| Q2 25 | 2.79× | — | ||
| Q1 25 | 34.71× | 3.79× | ||
| Q4 24 | — | -0.36× | ||
| Q3 24 | — | 2.64× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 12.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ONC
Segment breakdown not available.
SCSC
| Products And Services | $723.4M | 94% |
| Intelisys Advisory | $25.0M | 3% |
| Recurring Revenue | $18.2M | 2% |
